Brought to you by 
Merck to develop Neuromed's pain compound; ended
11 Jun 2009
Executive Summary
Neuromed (drugs to treat chronic pain) has licensed Merck & Co. exclusive worldwide development and commercialization rights to its lead pain candidate NMED160, an N-type calcium channel blocker that is in Phase II clinical trials. Merck also gets rights to develop and sell compounds for other neurological indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck to develop Neuromed's pain compound; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice